Statins Could Reduce Dementia Risk Even in People With Low Cholesterol
A new study has found a link between 'bad' cholesterol and the risk of dementia. It suggests that common cholesterol-lowering medicines, like statins, can help protect brain health as we age, even in those with low cholesterol already.
The new findings from researchers in Korea contribute to a controversial line of research, mostly based on observational studies. In the past, scientific investigations of dementia risk and levels of low-density lipoprotein cholesterol (LDL-C) have produced inconsistent results, and there is a need for rigorous, randomized controlled trials to clear up the confusion.
The current study is also observational, but its "robust" and "diverse" data support the 2024 Lancet Commission on dementia prevention, which highlighted cholesterol as a possible risk factor.
Led by neurophysiologist Minwoo Lee from Hallym University College of Medicine in Korea, the new study suggests that LDL-C levels are "directly associated with reduced dementia incidence, supporting cholesterol management as fundamental in preventing dementia."
The research retrospectively analyzed health data from 11 university hospitals in Korea, encompassing more than half a million individuals.
Those with LDL-C levels below 70 mg/dL showed a 26 percent decreased risk of all-cause dementia and a 28 percent decreased risk of Alzheimer's disease, compared to those with LDL-C levels above 130mg/dL.
This was true regardless of whether participants were taking statins or not. But when researchers looked at those taking cholesterol-lowering meds specifically, they found an intriguing correlation.
Statin use was associated with a 13 percent reduction in all-cause dementia and a 12 percent reduction in Alzheimer's risk compared to those who did not use the medicine. And this was true both for people who had high LDL-C levels and those who had low levels.
This indicates "a complex relationship between lipid levels and statin therapy in cognitive health," write the team of researchers, who hail from various clinics, hospitals, and universities in Korea.
While the study suggests cholesterol levels below 70 mg/dL may be protective to brain health, the use of statins may also improve dementia outcomes, even if a lower threshold of 'bad' cholesterol is not reached, or even if a person has low cholesterol already.
The results agree with some previous analyses but stand in contrast to other observational studies, like one published in 2023, which found that both low and high levels of high-density lipoprotein cholesterol (HDL-C) were associated with elevated dementia risk.
In fact, some observational studies have even found that cholesterol-lowering statins may increase the risk of dementia in those who already show cognitive decline.
The take-home message here is not clear-cut, and while the current research from Korea adds much-needed data to the conversation, the authors say we need specific, randomized controlled trials to dig further. Scientists also need to figure out how LDL cholesterol might be driving dementia in the brain at a molecular level.
An important gene that drives the risk of dementia, for instance, also carries cholesterol to the brain.
Neurophysiologist Francesco Tamagnini is studying the idea that damage to the blood-brain barrier can lead to an accumulation of LDL cholesterol in the brain, possibly causing amyloid beta proteins to cluster into plaques associated with Alzheimer's disease. Tamagnini was not involved in the current research, but he says "there is clearly more to the story of Alzheimer's than we first thought."
"The results give a convincing argument for researchers to consider LDL cholesterol in addition to the classic approaches," he writes in an independent review.
Julia Dudley is head of research at Alzheimer's Research UK, and she notes in another independent review that "dementia risk is complex and influenced by many factors. Without a detailed picture of what's going on in the brain we do not know if there is a direct link between lower cholesterol and reduced dementia risk."
"In the meantime," she adds, "keeping our hearts healthy remains one of the most effective ways we can protect our brain health. If you have any concerns about your cholesterol levels, you should speak to your GP."
The study was published in the Journal of Neurology, Neurosurgery & Psychiatry.
Review of Thousands of Studies Confirms Best Way to Keep Memory Sharp
Shock Link Found Between Marriage And Risk of Developing Dementia
Cutting Back on One Amino Acid Increased Lifespan in Middle-Aged Mice Up to 33%
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
20 minutes ago
- Time Magazine
Big Data Can Make America Healthier. Here's How to Do It Right
Big data can help make Americans healthier, and the Trump Administration has stated—in its recently released Make America Healthy Again report and elsewhere—that building a national big-data platform is one of its primary goals. As scientists who use large data sets to study health, we're excited about its potential and the willingness of the federal government to invest in it, particularly since big data has been underutilized in the U.S. compared with other developed countries—and since the number of ways it can be used grows nearly daily. It's a huge opportunity. But there are lots of concerns when assembling sensitive health data and combining it with other sensitive data, like credit scores, tax records, employment, educational records, and more. Some of those concerns with the Administration's plans have already surfaced. The Administration's first goal of assembling big data to studying autism has left some worried that if used inappropriately, such data could lead to harm, rather than help, for those with autism. Others worry that big data could be used to perform and justify shoddy research that supports predetermined conclusions without adhering to rigorous scientific methods—a concern reinforced by the discovery that the Make America Healthy Again report cited non-existent sources to support its claims. So how can we reap the benefits of big data while minimizing its risks? Here are some guiding principles: 1. Link the highly siloed health care and government data we already have The health care system already possesses health data on millions of Americans. Medical records are now almost always digitized, permitting doctors' notes, medical imaging, laboratory tests, insurance claims, and more to be linked (in theory) across doctors' offices, hospitals, nursing homes, and any other place people receive care. However, data collected about a patient in one setting often doesn't get connected to data from other settings—making it hard for researchers to get a full picture of what, exactly, is happening to each of us within the larger health care system. The federal government also has data on us that can be connected to health care data to answer important questions. For example, comprehensive and detailed data on Americans' occupations linked with health, insurance, and other data could help shed more light on relationships between our work and our health—helping to better answer curious questions like why taxi drivers are less likely to die from Alzheimer's disease or why female physicians don't outlive their male colleagues. The first step of making big data more helpful is to simply link the data—which, while possible, is difficult to accomplish without centralized effort. Once linkages have been made, data can be anonymized so that those studying sensitive questions aren't privy to confidential information about specific individuals. 2. Create capacity for researchers to securely link to other valuable data In addition to governmental data, many other sources of data can provide insights into our health. For example, smartwatches not only have data on how our hearts are beating (e.g., they can identify abnormal heart rhythms like atrial fibrillation), but they can also identify subtle changes in mobility that might be predictive of early neuromuscular diseases like Parkinson's disease. Meanwhile, grocery stores have data on the foods we eat, and with increasing interest in how diet affects our lives, these data could be linked to detailed measures of health. Similarly, social-media platforms possess data that can offer insights into changes in our mental health, and through large-scale analysis of online photos could even identify, in real time, early visible markers of disease. These are moonshots, of course, and whether we want to use data in this way is an open question. But the potential to improve health could be large. Creating a way for scientists to link outside data to existing government and health data—while responsibly maintaining individual anonymity after the linkage—could open many novel research opportunities. 3. Invest in data-research infrastructure Keeping all of these data sources organized, secure, and accessible to scientists is a tall order. Researchers who use big data often dedicate substantial resources to finding the data they need, organizing it, and ensuring its accuracy; the better the database is maintained, the easier it is for researchers to actually perform their analyses. The secure online platform where Medicare and other government health care data are currently accessed has been described by researchers as 'tedious and prone to system errors' and in need of major improvements. Meanwhile, security concerns have led the government to stop letting researchers store the data on their own secure servers, the easiest and most cost-effective way to actually work with the data. Access to Medicare data by researchers has become prohibitively expensive, costing about $30,000 a year or more for a single user to work on one project using the online platform. Proposals to drastically cut medical research funding have been reported, and if passed, these research funding cuts will come at the cost of discoveries to improve health that will never be made. High-quality research of any kind requires investment, whether it's in a biology lab under a microscope or working with data on powerful computers. A new data platform is only as valuable as researchers' ability to access it in a functional and cost-effective way. Any roadmap to designing a national data platform that links together health care and other sensitive data must consider the many valid concerns about collecting data in the U.S., including privacy concerns and how data will be used. The Pew Research Center finds that large majorities of Americans say they are concerned about how the government uses data collected about them (71%), while also admitting that they have little to no understanding of what the government even does with such data (77%). Here are some strategies—in addition to many of the cybersecurity and privacy safeguards already in place—to both protect the data and help earn the public trust: 1. Strictly limit data access to vetted researchers Mistrust and unease with government data collection is readily traceable to historical abuse of Americans' data (as well as recent allegations of improper access), so it's not surprising that many are wary of the Trump Administration's plans. Ensuring data cannot be weaponized by the government against individuals is perhaps the single biggest barrier to creating a useful database, but it can be done. Those currently using federal health care data must already undergo training and comply with very high data-security standards. Misuse of the data—such as even attempting to figure out the identity of an anonymous individual in the data—or failure to protect patient privacy can lead to criminal penalties. A platform of sensitive data without well-delineated restrictions on who can use it and what they can use it for is a recipe for problems. Other ongoing efforts by the Administration to compile data under the vague goal of 'increasing government efficiency' have been met with pushback and lawsuits from organizations concerned about data being used against members of the public. 2. Require analytical plans and ethics-board approval up front Current use of federal health data also requires researchers to provide the government detailed plans to justify the use of specific data. This allows the government to ensure that no more data than is needed to answer the specific question is provided to researchers. Researchers must also obtain ethical approval from an Institutional Review Board prior to accessing and analyzing data, a second checkpoint. These boards, which exist in light of egregious failures of medical research ethics in the 20 th century, help ensure that analyses are designed to minimize risk to patients—even if it is only their data, and not their bodies, at risk. 3. Emphasize true transparency Transparency into who is using this sensitive data and what exactly they are doing with it can engender trust between researchers and the American public. Just like researchers already do for clinical trials, those accessing the data platform should specify their plans in advance, and those plans should be easily and publicly available. Transparency around which data were accessed and what computer code was used to analyze it not only promotes trust, but such data- and code-sharing practices among researchers make it easier to appraise the quality of the work, identify mistakes, and root out misconduct. We can only assume that Americans' unease with governmental data use stems from knowledge that, as with all powerful tools, linked data has the potential to be used in potentially harmful ways. But when in the hands of qualified scientists using rigorous scientific methods and privacy safeguards, a robust real-world data platform like this could lead to new discoveries about how all of us can lead healthier lives.
Yahoo
4 hours ago
- Yahoo
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer's disease biomarker in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215), supporting the emerging link between CETP-inhibition and prevention of AD pathology -- -- NewAmsterdam to present results during the AAIC conference in July -- NAARDEN, The Netherlands and MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced positive topline data from prespecified Alzheimer's Disease ('AD') biomarker analyses in the Phase 3 BROADWAY clinical trial (NCT05142722). The pivotal Phase 3 BROADWAY study was primarily designed to evaluate the low-density lipoprotein cholesterol ('LDL-C') lowering efficacy of obicetrapib in adult patients with established atherosclerotic cardiovascular disease ('ASCVD') and/or heterozygous familial hypercholesterolemia ('HeFH'), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. As part of this pivotal registration trial for lowering LDL-C, a pre-specified sub-study was conducted to assess the effect of obicetrapib on plasma biomarkers of AD in both the full study population and in patients carrying the ApoE4 gene. 'These findings strongly support a potential preventive strategy for Alzheimer's disease,' said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. 'In this study obicetrapib, a potent CETP inhibitor, improved the progression of key plasma biomarkers of AD pathology over a 12-month period in patients with ASCVD. These data further differentiate obicetrapib and underscore the critical role CETP inhibition may have in mitigating the risk of AD progression, alongside the significant cardiovascular benefits obicetrapib has shown in our pivotal Phase 3 trials.' The AD sub-study results from BROADWAY build on genetic, Mendelian randomization, and NewAmsterdam's pre-clinical data and data from its Phase 2a clinical proof of concept trial. 'These findings have significant implications for AD prevention, especially for the over 25% of the population that carries one or two ApoE4 risk alleles and who currently lack FDA-approved prevention options,' said Philip Scheltens, professor emeritus at Amsterdam University Medical Center. 'The ability to reduce pathological biomarker progression suggests a potential to alter disease trajectory in this population, thereby delaying or preventing the onset of symptoms. The established safety profile of obicetrapib, demonstrated across multiple large clinical trials, combined with its oral administration, may greatly facilitate clinical implementation.' 'These results are the culmination of over two decades of dedicated scientific research. Approximately two thirds of patients with Alzheimer's disease carry the ApoE4 risk isoform that is associated with a much greater risk of developing AD, and the data shared today support our belief that CETP inhibition and specifically raising small functional HDL particles offers a novel and targeted approach to reducing that risk,' said John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer of NewAmsterdam. 'When viewed alongside the totality of evidence generated to date, including improvements in LDL-C, small LDL particles, Lipoprotein (a), and key biomarkers associated with diabetes and renal function, these novel data on the prevention of AD-associated pathology further strengthen obicetrapib's profile as a uniquely differentiated therapy with the potential to address multiple interrelated drivers of chronic cardiometabolic disease and neurodegeneration.' The Company plans to present the full results from the AD sub-study analysis in a Developing Topics oral presentation at the Alzheimer's Association International Conference in Toronto at the end of July 2025. Design of the Pivotal Phase 3 BROADWAY Clinical Trial The 52-week, global, pivotal, Phase 3, randomized, double-blind, placebo-controlled multicenter trial evaluated the efficacy and safety of 10 mg obicetrapib compared to placebo as an adjunct to maximally tolerated lipid-lowering therapies in patients with ASCVD and/or HeFH whose LDL-C is not adequately controlled. The trial was conducted at sites in North America, Europe, Asia and Australia. A total of 2,530 patients were randomized 2:1 to receive 10 mg obicetrapib or placebo dosed as a once-daily oral treatment, with or without food for 52 weeks. The mean baseline LDL-C for enrolled patients in the obicetrapib arm was approximately 100 mg/dL despite high intensity statin use reported by nearly 70% of patients during screening. Females comprised approximately 34% of the trial population and the median age of participants at baseline was 65 years. The primary endpoint was LS mean percent change from baseline in LDL-C of obicetrapib 10 mg compared to placebo after 84 days which showed a reduction of 33% with imputation. Secondary endpoints also included percent changes from baseline of obicetrapib 10 mg compared to placebo in ApoB, Lp(a), ApoA1, HDL-C, non-HDL-C, total cholesterol, and triglycerides at day 84, and on LDL-C levels at days 180 and 365. Other exploratory outcome measures included time from randomization until the first confirmed occurrence of MACE in the obicetrapib arm compared to placebo. The trial also evaluated the safety and tolerability profile of obicetrapib. Alzheimer's Sub-Study Trial In BROADWAY, a pre-specified AD sub-study was designed to assess plasma AD biomarkers in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified population of ApoE3/4 or 4/4 carriers. The sub-study included 1727 patients, including 367 ApoE4 carriers. The primary outcome measure was p-tau217 absolute and percent change over 12 months. Additional outcome measures included neurofilament light chain ('NFL'), glial fibrillary acidic protein ('GFAP'), p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215). Design of the Phase 2a Alzheimer's Trial The open-label and single-arm trial was designed to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of obicetrapib 10 mg in early AD patients carrying at least one copy of ApoE4. A total of 13 patients were given 10 mg obicetrapib and followed for 24 weeks. NewAmsterdam observed reductions in the levels of 24- and 27-hydroxycholestrol in both plasma and cerebrospinal fluid. Overall, obicetrapib was observed to be well-tolerated. No serious adverse events ('AEs') were reported, nor were any AEs considered to be related to the study drug. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Forward-Looking Statements Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company's business and strategic plans, the Company's commercial opportunity, the therapeutic and curative potential of the Company's product candidate, the Company's clinical trials and the timing for enrolling patients, the timing and forums for announcing data, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company's product candidate and the timing of expected regulatory and business milestones, including potential commercialization; whether topline, initial or preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, or whether projections regarding clinical outcomes will reflect actual results in future clinical trials or clinical use of our product candidate, if approved; the potential for varying interpretation of the AD sub-study results; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts; the effects of competition on the Company's future business; and those factors described in the Company's public filings with the Securities and Exchange Commission. Additional risks related to the Company's business include, but are not limited to: uncertainty regarding outcomes of the Company's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company's efforts to commercialize a product candidate; the Company's ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company's business; intellectual property related claims; the Company's ability to attract and retain qualified personnel; and ability to continue to source the raw materials for the Company's product candidate. If any of these risks materialize or the Company's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments may cause the Company's assessments to change. These forward-looking statements should not be relied upon as representing the Company's assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Yahoo
10 hours ago
- Yahoo
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
